628477951	628477951	CD	B-NP	O
|	|	NN	I-NP	O
GSH	GSH	NN	I-NP	O
|	|	NN	I-NP	O
30737210	30737210	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
5147835	5147835	CD	B-NP	O
|	|	CC	I-NP	O
3/3/2004	3/3/2004	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
HOCM	HOCM	NN	I-NP	I-protein
,	,	,	O	O
CHF	CHF	NN	B-NP	O
exacerbation	exacerbation	NN	I-NP	O
|	|	NN	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
3/3/2004	3/3/2004	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
2/3/2004	2/3/2004	CD	B-NP	O
******	******	SYM	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	O	O
BERCEGEAY	BERCEGEAY	NNP	B-NP	O
,	,	,	O	O
FRANK	FRANK	NNP	B-NP	O
057-99-62-7	057-99-62-7	CD	I-NP	O
Do	Do	NNP	I-NP	O
Wi	Wi	NNP	I-NP	O
Saint	Saint	NNP	I-NP	O
,	,	,	O	O
Texas	Texas	NNP	B-NP	O
10240	10240	CD	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
CAR	CAR	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
PATIENT	PATIENT	NN	I-NP	O
ON	ON	NN	I-NP	O
:	:	:	O	O
4/13/04	4/13/04	CD	B-NP	O
AT	AT	NN	I-NP	O
04	04	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NNP	I-NP	O
CONTINGENT	CONTINGENT	NNP	I-NP	O
UPON	UPON	NNP	I-NP	O
Not	Not	NNP	I-NP	O
Applicable	Applicable	NNP	I-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
BARER	BARER	NNP	B-NP	O
,	,	,	O	O
ISIDRO	ISIDRO	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
VERAPAMIL	VERAPAMIL	NN	B-NP	B-protein
SUSTAINED	SUSTAINED	VBD	B-VP	I-protein
RELEAS	RELEAS	NNP	B-NP	I-protein
240	240	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QD	QD	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	O
instructs	instruct	NNS	I-NP	O
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

K-DUR	K-DUR	NN	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
KCL	KCL	NNP	I-NP	O
SLOW	SLOW	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
20	20	CD	I-NP	O
MEQ	MEQ	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
As	As	IN	B-PP	O
per	per	IN	B-PP	O
LGH	LGH	NNP	B-NP	O
Potassium	Potassium	NNP	I-NP	O
Chloride	Chloride	NNP	I-NP	O
Policy	Policy	NNP	I-NP	O
:	:	:	O	O
each	each	DT	B-NP	O
20	20	CD	I-NP	O
mEq	mEq	NN	I-NP	O
dose	dose	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
with	with	IN	B-PP	O
4	4	CD	B-NP	O
oz	oz	NN	I-NP	O
of	of	IN	B-PP	O
fluid	fluid	NN	B-NP	B-DNA
METFORMIN	METFORMIN	NN	I-NP	I-DNA
500	500	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
BID	BID	NNP	I-NP	I-DNA
ZYRTEC	ZYRTEC	NNP	I-NP	I-DNA
-LRB-	-LRB-	NNP	I-NP	I-DNA
CETIRIZINE	CETIRIZINE	NNP	I-NP	I-DNA
-RRB-	-RRB-	NNP	I-NP	I-DNA
10	10	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
QD	QD	NNP	I-NP	I-DNA
Food/Drug	Food/Drug	NNP	I-NP	I-DNA
Interaction	Interaction	NNP	I-NP	I-DNA
Instruction	Instruction	NNP	I-NP	I-DNA
Avoid	Avoid	NNP	I-NP	I-DNA
grapefruit	grapefruit	NN	I-NP	I-DNA
unless	unless	IN	B-SBAR	I-DNA
MD	MD	NN	B-NP	I-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

Number	Number	NN	B-NP	O
of	of	IN	B-PP	O
Doses	Dose	NNS	B-NP	O
Required	Require	VBN	B-VP	O
-LRB-	-LRB-	HYPH	B-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
4	4	CD	B-NP	O
SINGULAIR	SINGULAIR	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
MONTELUKAST	MONTELUKAST	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
10	10	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
VENLAFAXINE	VENLAFAXINE	NN	I-NP	O
EXTENDED	EXTENDED	VBD	B-VP	O
RELEASE	RELEASE	NN	B-NP	O
37.5	37.5	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
Number	Number	NNP	I-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
3	3	CD	B-NP	O
ADVAIR	ADVAIR	NN	I-NP	O
DISKUS	DISKUS	IN	B-PP	O
250/50	250/50	CD	B-NP	O
-LRB-	-LRB-	SYM	I-NP	O
FLUTICASONE	FLUTICASONE	NN	I-NP	O
PROPIONATE	PROPIONATE	NN	I-NP	O
/	/	SYM	B-NP	O
...	...	:	O	B-protein
-RRB-	-RRB-	SYM	B-NP	I-protein
1	1	CD	I-NP	I-protein
PUFF	PUFF	NN	I-NP	I-protein
INH	INH	NN	I-NP	I-protein
BID	BID	NN	I-NP	I-protein
LASIX	LASIX	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
FUROSEMIDE	FUROSEMIDE	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
20	20	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QD	QD	NNP	I-NP	I-protein
VENTOLIN	VENTOLIN	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
ALBUTEROL	ALBUTEROL	NNP	I-NP	I-protein
INHALER	INHALER	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
2	2	CD	I-NP	I-protein
PUFF	PUFF	NN	I-NP	I-protein
INH	INH	NN	I-NP	I-protein
QID	QID	NN	I-NP	I-protein
LIPITOR	LIPITOR	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
ATORVASTATIN	ATORVASTATIN	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
80	80	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QD	QD	NNP	I-NP	O
Instructions	Instruction	NNPS	I-NP	O
:	:	:	O	O
10mg	10mg	CD	B-NP	O
qd	qd	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NNP	B-NP	O
/	/	SYM	B-NP	O
Low	Low	JJ	I-NP	O
chol/low	chol/low	NN	I-NP	O
sat	sat	NN	I-NP	O
.	.	.	O	O

fat	fat	JJ	B-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NN	B-NP	O
/	/	SYM	O	O
ADA	ADA	NN	B-NP	O
1800	1800	CD	I-NP	O
cals/dy	cals/dy	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
2	2	CD	B-NP	O
gram	gram	NN	I-NP	O
Sodium	Sodium	NN	I-NP	O
RETURN	RETURN	NN	I-NP	O
TO	TO	NN	I-NP	O
WORK	WORK	NN	I-NP	O
:	:	:	O	O
Immediately	Immediately	RB	B-ADVP	O
FOLLOW	FOLLOW	NNP	B-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Elbert	Elbert	NNP	I-NP	O
Mantel	Mantel	NNP	I-NP	O
1-2	1-2	NN	I-NP	O
weeks	week	NNS	I-NP	O
,	,	,	O	O
ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
broccoli	broccoli	NNS	B-NP	O
,	,	,	O	O
Aspirin	Aspirin	NN	B-NP	O
ADMIT	ADMIT	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
PRINCIPAL	PRINCIPAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
HOCM	HOCM	NNP	I-NP	O
,	,	,	O	O
CHF	CHF	NN	B-NP	O
exacerbation	exacerbation	NN	I-NP	O
OTHER	OTHER	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
HOCM	HOCM	NNP	I-NP	O
,	,	,	O	O
mild	mild	JJ	B-NP	O
asthma	asthma	NN	I-NP	O
,	,	,	O	O
CHF	CHF	NN	B-NP	B-protein
,	,	,	O	O
type	type	NN	B-NP	O
II	II	CD	I-NP	O
DM	DM	NN	I-NP	O
,	,	,	O	O
morbid	morbid	JJ	B-NP	O
obesity	obesity	NN	I-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
none	none	NN	B-NP	O
OTHER	OTHER	NN	I-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
none	none	NN	I-NP	O
BRIEF	BRIEF	NN	I-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
52F	52F	NN	B-NP	O
with	with	IN	B-PP	O
HOCM	HOCM	NN	B-NP	O
,	,	,	O	O
peak	peak	JJ	B-NP	O
gradient	gradient	NN	I-NP	O
125	125	CD	I-NP	O
mmHg	mmHg	NN	I-NP	O
on	on	IN	B-PP	O
TTE	TTE	NN	B-NP	O
in	in	IN	B-PP	O
6/29	6/29	CD	B-NP	O
,	,	,	O	O
CHF	CHF	NN	B-NP	B-protein
,	,	,	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
morbid	morbid	NN	B-NP	O
obesity	obesity	NN	I-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
new	new	JJ	B-NP	O
type	type	NN	I-NP	O
II	II	CD	I-NP	O
DM	DM	NN	I-NP	O
,	,	,	O	O
recently	recently	RB	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
furosemide	furosemide	NN	B-NP	O
for	for	IN	B-PP	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
with	with	IN	B-PP	O
subsequent	subsequent	JJ	B-NP	O
30-lb	30-lb	JJ	I-NP	O
+	+	JJ	I-NP	O
wt	wt	NN	I-NP	O
loss	loss	NN	I-NP	O
,	,	,	O	O
admitted	admit	VBN	B-VP	O
with	with	IN	B-PP	O
increasing	increase	VBG	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
orthopnea	orthopnea	NN	B-NP	O
,	,	,	O	O
DOE	DOE	NNP	B-NP	O
,	,	,	O	O
5-lb	5-lb	NN	B-NP	O
wt	wt	NN	I-NP	O
gain	gain	NN	I-NP	O
x	x	SYM	B-VP	O
2	2	CD	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
wks	wk	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
significant	significant	JJ	B-NP	O
wt	wt	NN	I-NP	O
gain	gain	NN	I-NP	O
noted	note	VBD	B-VP	O
,	,	,	O	O
and	and	CC	O	O
dyazide	dyazide	NN	B-NP	O
changed	change	VBD	B-VP	O
to	to	TO	B-PP	O
furosemide	furosemide	NN	B-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
subsequent	subsequent	JJ	B-NP	O
30-lb	30-lb	JJ	I-NP	O
wt	wt	NN	I-NP	O
loss	loss	NN	I-NP	O
since	since	IN	B-PP	O
April	April	NNP	B-NP	O
.	.	.	O	O

Over	Over	IN	B-PP	O
last	last	JJ	B-NP	O
2	2	CD	I-NP	O
days	day	NNS	I-NP	O
has	have	VBZ	B-VP	O
felt	feel	VBN	I-VP	O
increasing	increase	VBG	B-NP	O
SOB	SOB	NN	I-NP	B-protein
,	,	,	O	O
orthopnea	orthopnea	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
5-lb	5-lb	NN	B-NP	B-protein
wt	wt	NN	I-NP	I-protein
gain	gain	NN	I-NP	I-protein
from	from	IN	B-PP	O
307	307	CD	B-NP	O
-	-	HYPH	B-PP	O
>	>	SYM	B-NP	O
311	311	CD	B-NP	O
.	.	.	O	O

Also	Also	RB	B-NP	O
wheezing	wheezing	JJ	I-NP	O
,	,	,	I-NP	O
non-productive	non-productive	JJ	I-NP	O
cough	cough	NN	I-NP	O
,	,	,	O	O
post-nasal	post-nasal	JJ	B-NP	O
drip	drip	NN	I-NP	O
;	;	:	O	O
no	no	DT	B-NP	O
fevers/chills	fevers/chill	NNS	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
has	have	VBZ	B-VP	O
increased	increase	VBN	I-VP	O
fluid	fluid	NN	B-NP	O
intake	intake	NN	I-NP	O
by	by	IN	B-PP	O
10	10	CD	B-NP	O
glasses	glass	NNS	I-NP	O
of	of	IN	B-PP	O
water	water	NN	B-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
near-syncope	near-syncope	NN	I-NP	O
since	since	IN	B-PP	O
2002	2002	CD	B-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
chest	chest	NN	I-NP	O
pressure/pain	pressure/pain	NN	I-NP	O
,	,	,	O	O
rare	rare	JJ	B-NP	O
palpitations	palpitation	NNS	I-NP	O
.	.	.	O	O

Other	Other	JJ	B-NP	O
PMH	PMH	NN	I-NP	O
:	:	:	O	O
depression	depression	NN	B-NP	O
,	,	,	O	O
R	R	NN	B-NP	B-protein
TKR	TKR	NN	I-NP	I-protein
.	.	.	O	O

Exam	Exam	NN	B-NP	O
:	:	:	O	O
98.6	98.6	CD	B-NP	O
148/73	148/73	CD	I-NP	O
79	79	CD	I-NP	O
25	25	CD	I-NP	O
93	93	CD	I-NP	O
%	%	NN	I-NP	O
RA	RA	NN	I-NP	O
.	.	.	O	O

Comfortable	Comfortable	JJ	B-NP	O
,	,	,	I-NP	O
full	full	JJ	I-NP	O
sentences	sentence	NNS	I-NP	O
.	.	.	O	O

JVP	JVP	NN	B-NP	O
diff	diff	NN	I-NP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
;	;	:	O	O
chest	ch	JJS	B-ADJP	O
clear	clear	JJ	I-ADJP	O
;	;	:	O	O
II/VI	II/VI	NNP	B-NP	O
sys	sy	VBZ	B-VP	O
M	M	NNP	B-NP	O
LSB	LSB	NNP	I-NP	O
increased	increase	VBD	B-VP	O
w/valsalva	w/valsalva	NN	B-NP	O
,	,	,	O	O
decreased	decrease	VBD	B-VP	O
with	with	IN	B-PP	O
leg	leg	NN	B-NP	O
raise	raise	NN	I-NP	O
.	.	.	O	O

Obese	Obese	JJ	B-NP	O
abd	abd	NN	I-NP	O
,	,	,	O	O
1	1	CD	B-NP	O
+	+	SYM	I-NP	O
LE	LE	NN	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

CXR	CXR	NN	B-NP	O
mod	mod	NN	I-NP	O
cardiomegaly	cardiomegaly	RB	B-ADVP	O
,	,	,	O	O
no	no	DT	B-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	O
:	:	:	O	O
NSR	NSR	NN	B-NP	B-DNA
@	@	NN	I-NP	I-DNA
76	76	CD	B-NP	I-DNA
,	,	,	O	O
unchanged	unchanged	JJ	B-NP	O
TWF/I	TWF/I	NN	I-NP	O
V5-V6	V5-V6	NN	I-NP	O
.	.	.	O	O

*****	*****	SYM	O	O
Assessment	Assessment	NN	B-NP	O
and	and	CC	I-NP	O
Hospital	Hospital	NN	I-NP	O
Course	Course	NN	I-NP	O
*****	*****	SYM	O	O
52	52	CD	B-NP	O
yo	yo	NN	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
increasing	increase	VBG	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
weight	weight	NN	B-NP	O
gain	gain	NN	I-NP	O
in	in	IN	B-PP	O
setting	setting	NN	B-NP	O
of	of	IN	B-PP	O
increasing	increase	VBG	B-NP	O
fluid	fluid	NN	I-NP	O
intake	intake	NN	I-NP	O
:	:	:	O	O
**	**	SYM	B-NP	O
CV	CV	NN	I-NP	O
:	:	:	O	O
Pump	Pump	NN	B-NP	O
:	:	:	O	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
CHF	CHF	NN	B-NP	B-protein
,	,	,	O	O
excessive	excessive	JJ	B-NP	O
fluid	fluid	NN	I-NP	O
intake	intake	NN	I-NP	O
likely	likely	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
to	to	TO	B-PP	O
new	new	JJ	B-NP	O
onset	onset	NN	I-NP	O
DM	DM	NN	I-NP	O
.	.	.	O	O

Diuresed	Diurese	VBN	B-VP	O
with	with	IN	B-PP	O
20mg	20mg	NN	B-NP	O
lasix	lasix	NN	I-NP	O
IV	IV	CD	I-NP	O
in	in	IN	B-PP	O
ED	ED	NNP	B-NP	O
,	,	,	O	O
40mg	40mg	CD	B-NP	O
IV	IV	CD	I-NP	O
lasix	lasix	NN	I-NP	O
on	on	IN	B-PP	O
floor	floor	NN	B-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
resolution	resolution	NN	B-NP	O
of	of	IN	B-PP	O
orthopnea	orthopnea	NN	B-NP	O
and	and	CC	I-NP	O
DOE	DOE	NN	I-NP	O
.	.	.	O	O

Maintained	Maintain	VBN	B-VP	O
on	on	IN	B-PP	O
verapamil	verapamil	NN	B-NP	O
for	for	IN	B-PP	O
ventricular	ventricular	JJ	B-NP	O
relaxation	relaxation	NN	I-NP	O
.	.	.	O	O

Will	Will	MD	O	O
see	see	VBP	B-VP	O
Dr.	Dr.	NNP	B-NP	O
Rullan	Rullan	NNP	I-NP	O
as	as	IN	B-PP	O
outpatient	outpatient	NN	B-NP	O
for	for	IN	B-PP	O
potential	potential	JJ	B-NP	O
ablation	ablation	NN	I-NP	O
of	of	IN	B-PP	O
HOCM	HOCM	NN	B-NP	B-protein
.	.	.	O	O

Seen	Seen	NNP	B-NP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Efren	Efren	NNP	I-NP	O
Stachnik	Stachnik	NNP	I-NP	O
genetic	genetic	JJ	I-NP	O
counselor	counselor	NN	I-NP	O
to	to	TO	B-VP	O
discuss	discuss	VB	I-VP	O
genotyping	genotyping	NN	B-NP	O
of	of	IN	B-PP	O
HOCM	HOCM	NN	B-NP	O
,	,	,	O	O
for	for	IN	B-PP	O
herself	herself	PRP	B-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
children	child	NNS	I-NP	O
.	.	.	O	O

-	-	HYPH	B-NP	O
Isch	Isch	NN	I-NP	O
:	:	:	O	O
low	low	JJ	B-NP	O
suspicion	suspicion	NN	I-NP	O
,	,	,	O	O
ruled	rule	VBD	B-VP	O
out	out	RP	B-PRT	O
by	by	IN	B-PP	O
enzymes	enzyme	NNS	B-NP	B-protein
.	.	.	O	O

Continued	Continue	VBN	B-NP	O
verapamil	verapamil	NN	I-NP	O
for	for	IN	B-PP	O
HTN	HTN	NN	B-NP	B-protein
.	.	.	O	O

-	-	HYPH	B-NP	O
Pump	Pump	NN	I-NP	O
:	:	:	O	O
no	no	DT	B-NP	O
issues	issue	NNS	I-NP	O
--	--	:	O	O
in	in	IN	B-PP	O
NSR	NSR	NN	B-NP	B-protein
during	during	IN	B-PP	O
entire	entire	JJ	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

**	**	SYM	B-NP	O
Pulm	Pulm	NN	I-NP	O
:	:	:	O	O
PFTs	PFT	NNS	B-NP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
restrictive	restrictive	JJ	B-NP	O
pattern	pattern	NN	I-NP	O
--	--	:	O	O
TLC	TLC	NN	B-NP	O
56	56	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
FVC	FVC	NN	B-NP	O
59	59	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
FEV1	FEV1	NN	B-NP	O
57	57	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
FEV1/FVC	FEV1/FVC	NN	B-NP	O
100	100	CD	I-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
DLCO	DLCO	NNP	B-NP	O
corrected	correct	VBD	B-VP	O
66	66	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O
?	?	.	O	O

May	May	MD	O	O
benefit	benefit	NN	B-NP	O
from	from	IN	B-PP	O
outpatient	outpatient	NN	B-NP	O
referral	referral	NN	I-NP	O
for	for	IN	B-PP	O
sleep	sleep	JJ	B-NP	O
study	study	NN	I-NP	O
for	for	IN	B-PP	O
OSA/OHS	OSA/OHS	NNP	B-NP	O
.	.	.	O	O

Continued	Continue	VBN	B-NP	O
outpatient	outpatient	NN	I-NP	O
regimen	regimen	NN	I-NP	O
of	of	IN	B-PP	O
singulair	singulair	NN	B-NP	O
,	,	,	O	O
zyrtec	zyrtec	NN	B-NP	O
,	,	,	O	O
atrovent	atrovent	NN	B-NP	O
,	,	,	O	O
albuterol	albuterol	NN	B-NP	O
,	,	,	O	O
advair	advair	NN	B-NP	O
.	.	.	O	O

**	**	SYM	B-NP	O
Endocrine	Endocrine	NN	I-NP	O
:	:	:	O	O
new	new	JJ	B-NP	O
type	type	NN	I-NP	O
II	II	CD	I-NP	O
DM	DM	NN	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
significant	significant	JJ	B-NP	O
polydipsia	polydipsia	NN	I-NP	O
likely	likely	RB	B-VP	O
contributing	contribute	VBG	I-VP	O
to	to	TO	B-PP	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
.	.	.	O	O

Increased	Increase	VBN	B-NP	O
metformin	metformin	NN	I-NP	O
to	to	TO	B-PP	O
500mg	500mg	CD	B-NP	O
bid	bid	NN	I-NP	O
.	.	.	O	O

**	**	SYM	B-NP	O
FEN	FEN	NN	I-NP	O
:	:	:	O	O
discussed	discuss	VBN	B-NP	O
outpatient	outpatient	NN	I-NP	O
weight	weight	NN	I-NP	O
loss	loss	NN	I-NP	O
program	program	NN	I-NP	O
for	for	IN	B-PP	O
morbid	morbid	JJ	B-NP	O
obesity	obesity	NN	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Garst	Garst	NNP	I-NP	O
attempt	attempt	NN	I-NP	O
to	to	TO	B-VP	O
arrange	arrange	VB	I-VP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

**	**	SYM	B-NP	O
Psych	Psych	NN	I-NP	O
:	:	:	O	O
cont	cont	VB	B-VP	O
venlafaxine	venlafaxine	NN	B-NP	O
for	for	IN	B-PP	O
depression	depression	NN	B-NP	O
**	**	SYM	I-NP	O
PPX	PPX	NN	I-NP	B-protein
:	:	:	O	O
lovenox	lovenox	NN	B-NP	O
,	,	,	O	O
nexium	nexium	NN	B-NP	O
ADDITIONAL	ADDITIONAL	NN	I-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
Please	Please	NNP	B-NP	O
call	call	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Weiner	Weiner	NNP	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
follow-up	follow-up	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
in	in	IN	B-PP	O
1-2	1-2	CD	B-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

Please	Please	NNP	B-NP	O
call	call	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Shelton	Shelton	NNP	I-NP	O
Winesett	Winesett	NNP	I-NP	O
office	office	NN	I-NP	O
at	at	IN	B-PP	O
404-812-5799	404-812-5799	CD	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Baese	Baese	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
to	to	TO	B-VP	O
set	set	VB	I-VP	O
up	up	RP	B-PRT	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
ablation	ablation	NN	I-NP	O
of	of	IN	B-PP	O
your	your	PRP$	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Adalberto	Adalberto	NNP	I-NP	O
Czaplinski	Czaplinski	NNP	I-NP	O
number	number	NN	I-NP	O
is	be	VBZ	B-VP	O
-LRB-	-LRB-	SYM	B-ADJP	O
419	419	CD	B-NP	O
-RRB-	-RRB-	SYM	I-NP	O
832-1474	832-1474	CD	I-NP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
you	you	PRP	B-NP	O
would	would	MD	B-VP	O
like	like	VB	I-VP	O
to	to	TO	I-VP	O
speak	speak	VB	I-VP	O
further	further	RBR	B-ADVP	O
about	about	IN	B-PP	O
genotyping	genotype	VBG	B-VP	O
your	your	PRP$	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
obtaining	obtain	VBG	B-VP	O
genetic	genetic	JJ	B-NP	O
tests	test	NNS	I-NP	O
on	on	IN	B-PP	O
your	your	PRP$	B-NP	O
children	child	NNS	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
HAMMERSTONE	HAMMERSTONE	NNP	B-NP	O
,	,	,	O	O
NORMAND	NORMAND	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
CA94	CA94	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
4/13/04	4/13/04	CD	I-NP	O
@	@	NN	I-NP	O
03	03	CD	I-NP	O
:	:	:	O	O
34	34	CD	B-NP	O
PM	PM	NN	I-NP	O
******	******	SYM	B-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

